Academic Background Renal Cell Carcinoma (RCC) is one of the cancers with a rapidly rising incidence globally, particularly among young patients and minorities. In the United States, an estimated 81,610 new cases of RCC will be diagnosed in 2024, with approximately 30% progressing to metastatic RCC. For locally advanced RCC, the initial treatment i...

Inhibition of JAK2/mTOR Fails to Effectively Prevent Acute Graft-versus-Host Disease (GVHD): Limitations of Targeting Th1/Th17 Cells In recent years, the role of systemic immunosuppressive therapies in preventing acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell transplantation (alloHCT) has come under scrutiny. Th1 (T...

Revumenib Alters the Treatment Landscape for KMT2A-Rearranged Leukemia Academic Background Leukemia is a malignant disease caused by abnormalities in the hematopoietic system, with KMT2A-rearranged (KMT2A-r) leukemia being a common subtype, particularly in pediatric and adult acute myeloid leukemia (AML). Rearrangements of the KMT2A gene (lysine me...

Academic Background and Problem Statement In recent years, immune checkpoint inhibitors (ICIs) have made significant progress in cancer treatment, particularly anti-PD-1 and anti-PD-L1 antibodies, which have become the standard of care for first-line treatment in various cancers. However, despite the notable clinical activity of these therapies in ...

Review of Two New Studies on ONC201 Treatment for H3K27M-Mutant Diffuse Midline Glioma (H3K27M-DMG) This review reports on two new studies investigating the small molecule compound ONC201 for the treatment of H3K27M-mutant diffuse midline glioma (H3K27M-DMG). Background: H3K27M-DMG is an aggressive primary brain tumor that predominantly affects chi...